Lumida
/RHHBY
⌘K
Roche Holding AG

Roche Holding AG

RHHBY
$51.60USD↑+0.29%+0.15 today

MARKET CAP

258.9B

P/E (TTM)

1.3x

FWD P/E

1.2x

DAY RANGE

$51 – $52

52W RANGE

$36
$59

AI Summary

Stalk
StalkMedium

We maintain a bullish medium-term bias in Stage 2 corrective reset as price consolidates around the 9 and 20 EMAs and the rising 50 DMA, reflecting structural repair within the long-term uptrend. Near-term, the stock is range-bound with flat EMAs and neutral momentum, offering no clear execution edge. We will stalk pullbacks into the EMA and 50 DMA confluence for tactical entry. Key risks include a decisive breakdown below these moving averages, which would signal deeper correction and potential transition to Stage 3.

  • ↑Pharma revenue reached CHF 35.6 B, up 9% YoY; international sales +13%.
  • ↑10 pipeline molecules moved into Phase III, signaling robust R&D momentum.
  • ↓Diagnostics revenues plunged 27% in China; single-digit decline expected in 2025.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Roche Holding AG (OTCQX:RHHBY) is a leading global healthcare company specializing in pharmaceuticals and diagnostics. It is particularly prominent in areas such as oncology, immunology, and neurology, with a strong commitment to innovative solutions and meeting unmet medical needs. Roche's diversified portfolio of products, bolstered by its robust pipeline, positions it favorably in the competitive landscape of the healthcare sector, particularly in oncology where it maintains significant market share.

Bull says

  • ↑Pharma revenue reached CHF 35.6 B, up 9% YoY; international sales +13%.
  • ↑10 pipeline molecules moved into Phase III, signaling robust R&D momentum.
  • ↑Core EPS guidance raised to low-double-digit growth, reflecting strong cost control.
  • ↑Oncology franchise grew 15%, led by Phesgo’s ~60% global conversion rate.
  • ↑Dividend yield ~0.9% and strong cash flow support shareholder returns.
  • ↑Positive momentum and strong profitability metrics suggest near-term upside.

Bear says

  • ↓Diagnostics revenues plunged 27% in China; single-digit decline expected in 2025.
  • ↓Loss of exclusivity risks pegged at CHF 800 M could erode core sales.
  • ↓HER2 franchise set to peak near CHF 9 B then decline, highlighting competition risk.
  • ↓Negative earnings yield and worsening revenue growth raise valuation concerns.
  • ↓Analyst revisions are negative and high short interest signals bearish sentiment.
  • ↓Intensifying competition from Pfizer and Novartis may pressure market share.

Investment themes with RHHBY

Pharmaceuticals↓ -0.08%

Drug development driving global healthcare solutions

LLY · JNJ · MRK
Others↑ +0.32%

Miscellaneous or uncategorized companies

ATAI · SVIX · SVXY

Earnings Call · Q3 2025 · Mgmt. Guidance

Updated 07-10-2026neutral

Transcript signals

Bull points

  • 9% in constant rates
  • plus 7% in constant rates
  • pharma sales grew by 9% at constant exchange rates, reaching CHF 35.6 billion

Bear points

  • we think that the new indication for full year should be an CHF 800 million loss due to the loss of exclusivities
  • the data that was recently shared from competitors, in particular, DESTINY-05, will have a negative impact to Kadcyla of roughly CHF 700 million to CHF 1 billion over time
  • we now expect to see flat to low single-digit growth for Tecentriq in the coming years
Read full transcript analysis ›